Source - LSE Regulatory
RNS Number : 5575A
MaxCyte, Inc.
02 June 2021
 

 

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

 

Total Voting Rights

 

 

Gaithersburg, Maryland - 2 June 2021: MaxCyte (LSE: MXCT, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission facility, details of which were announced on 2 May 2017, it has recently issued 34,722 shares of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

 

The new Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the recent issue of the new Common Stock is 84,719,345 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

 

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 84,389,345 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.  

 

For further information, please contact:

 



MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

 

+1 301 944 1660

 

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

 

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

+44 (0)20 7260 1000

 

Joint Corporate Broker

Stifel Nicolaus Europe Limited

Healthcare Investment Banking

Nicholas Moore / Ben Maddison / Samira Essebiyea

Corporate Broking

Nick Adams  

 

 

+44 (0) 20 7710 7600


 

 

About MaxCyte

 

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted research and clinical licences with academic and industry customers covering over an estimated 140 programs, and clinical licences with academic and industry customers covering over an estimated 100 programs being developed for use in humans. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDKBBDFBKKPAK
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.